LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1694 | 10776 | 11103 | 0.9705 | 0.9781 |
MCF 10A | Brivanib | 0.12 | uM | LJP5 | 72 | hr | 1694 | 10774 | 11103 | 0.9704 | 0.9779 |
MCF 10A | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11133 | 11103 | 1.0027 | 1.0020 |
Hs 578T | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 765 | 3069 | 3148 | 0.9750 | 0.9751 |
BT-20 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 1334 | 3831 | 4033 | 0.9506 | 0.9379 |
BT-20 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 2698 | 4033 | 0.6696 | 0.5555 |
Hs 578T | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 765 | 2123 | 3148 | 0.6743 | 0.6487 |
Hs 578T | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 765 | 698 | 3148 | 0.2219 | -0.0455 |
Hs 578T | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 765 | 2597 | 3148 | 0.8249 | 0.8199 |
Hs 578T | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 765 | 388 | 3148 | 0.1232 | -0.2835 |
BT-20 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4150 | 4033 | 1.0287 | 1.0355 |
BT-20 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 1273 | 4033 | 0.3157 | -0.0294 |
Hs 578T | Buparlisib | 10 | uM | LJP5 | 72 | hr | 765 | 331 | 3148 | 0.1051 | -0.3367 |
BT-20 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1334 | 612 | 4033 | 0.1519 | -0.3867 |
Hs 578T | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 765 | 2958 | 3148 | 0.9396 | 0.9399 |
BT-20 | Buparlisib | 10 | uM | LJP5 | 72 | hr | 1334 | 463 | 4033 | 0.1148 | -0.4855 |
MDA-MB-231 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4524 | 5079 | 0.8907 | 0.8849 |
MDA-MB-231 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 2763 | 5079 | 0.5439 | 0.4643 |
MDA-MB-231 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4960 | 5079 | 0.9767 | 0.9761 |
MDA-MB-231 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 1607 | 5079 | 0.3163 | 0.1090 |
SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5577 | 5752 | 0.9696 | 0.9479 |
SK-BR-3 | Buparlisib | 10 | uM | LJP5 | 72 | hr | 2543 | 1222 | 5752 | 0.2125 | -0.4633 |
MDA-MB-231 | Buparlisib | 10 | uM | LJP5 | 72 | hr | 1311 | 735 | 5079 | 0.1447 | -0.2566 |
SK-BR-3 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 2940 | 5752 | 0.5110 | 0.1305 |
SK-BR-3 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4773 | 5752 | 0.8299 | 0.7071 |